EUnetHTA Early Dialogues – Status during EUnetHTA prolongation period
The current pandemic situation has put additional strain on European health systems and HTA bodies have not been immune to this impact. The unfortunate result of this has been the temporary suspension of EUnetHTA Early Dialogues (EDs). We are pleased to announce that the EUnetHTA Executive Board has recognized the interest to continue to offer […]
RCR OT 01 – “Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” – final assessment now available
EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” is now available. This is the first rapid review assessing health technologies for SARS-CoV-2. The general objective of this assessment was to provide a reliable synthesis of the […]
OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available
EUnetHTA is pleased to announce that the OTCA21 Final Assessment is now available for access. The assessed technology is Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea. The aim of this assessment was to evaluate effectiveness and safety of HGNS compared with no treatment in those adult patients with moderate-to-severe obstructive sleep apnea […]
PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. […]
Patient group input requested for a new EUnetHTA Assessment on surgical techniques and devices for the treatment of benign prostatic hyperplasia.
EUnetHTA deems patient involvement very important in the production of Joint/Collaborative Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
EMA-EUnetHTA Bilateral Meeting – November 2019 – documentation now available
The minutes from the EMA-EUnetHTA Bilateral Meeting, hosted by EUnetHTA at the Zorginstituut Nederland (ZIN) in Diemen, Netherlands, on 21st November, 2019, are now available for access. Topics discussed included a follow-up on registries, patient-reported outcomes as part of evidence generation plans, PLEG, and more. In addition, a review on EMA-EUnetHTA activities in the context […]
Declaration of Confidentiality – FAQ now available
A list of Frequently Asked Questions on Declaration of Interest is now available to accompany and inform the confidentiality process. Follow the link for more information: https://www.eunethta.eu/doi/
EUnetHTA 2019 Forum Paper now available for access
We are happy to announce that our paper, ‘The fourth edition of the European Network for Health Technology Assessment: highlights and outcomes’, has been published this week on the International Journal of Technology Assessment in Health Care. The paper is available at this link: Thank you for your cooperation and congratulations to all those involved. Giovanni […]
“Healthcare Professional Involvement in Relative Effectiveness Assessments” is now published and available for access
At the request of the EUnetHTA Executive Board, a cross-work package (WP) task group on the involvement of Health Care Providers (HCP) and Patients & Consumers (P&C) was established in Fall 2017. The task group includes representatives from WP1, WP2, WP4, and WP5. The task group is operational in nature and the scope is involvement […]
Statement on the Joint Action 3 Prolongation
EUnetHTA Joint Action 3 has received official approval from Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) for an extension of an additional 12 months without additional funding. This prolongation is meant to allow the finalisation of outstanding deliverables and, where possible, further prepare for a future European HTA system. The Executive Board is currently […]
